Strategies to Optimize the Dose Design Process to Create Better Treatments
Tuesday, July 27th - 9am EDT
|
Sponsored By:
|
|
Traditional dosage form design and development is largely driven by cost and timelines. However, there are several additional considerations that are often overlooked, impacting the long-term success of a drug product. Enlisting the help of expert partners to advise on these considerations could increase the likelihood of drug product success.
In this presentation case studies will be shared to demonstrate how the right guidance, at the right time, can help drug developers create better treatments. The expert will also introduce Catalent’s new OptiDose™ Design Solution, a new scientific tool that combines pharmaceutics, dose form design and characteristics from the target patient group to support decision-making during dose design.
In this presentation case studies will be shared to demonstrate how the right guidance, at the right time, can help drug developers create better treatments. The expert will also introduce Catalent’s new OptiDose™ Design Solution, a new scientific tool that combines pharmaceutics, dose form design and characteristics from the target patient group to support decision-making during dose design.
Speaker
Lisa Caralli
Catalent, Director of Science and Technology, Pharmaceutics
Lisa Caralli
Catalent, Director of Science and Technology, Pharmaceutics
Lisa Caralli is Science and Technology Director, Pharmaceutics at Catalent San Diego. She has over 28 years of industry experience in pharmaceutical research and development. Lisa's area of expertise is analytical methods and formulation development of small molecules and peptides. In her role, she works with pharmaceutical companies to identify the right development pathway for their early development drug candidates and advances new technical offerings within Catalent. Prior to joining the San Diego site over 15 years ago, Lisa was an Analytical Project Manager at Ionis Pharmaceuticals where she worked on the chemistry, manufacturing and controls of antisense (oligonucleotide) drugs. Lisa joined Ionis from Amylin Pharmaceuticals where she directed their amino acid analysis core facility and performed methods development for peptide-drug candidates. She began her career at the Immune Response Corporation studying biological markers of autoimmune diseases. Lisa holds a B.S. in Biochemistry from the University of California at Davis.
